Advances and challenges in precision medicine in salivary gland cancer

Salivary gland cancer (SGC) is a distinct but heterogeneous group of malignancies comprising approximately 6.5% of cases within head and neck cancer [1]. This makes it a rare cancer, with an estimated age-standardized annual incidence of less than 2/100.000 in most countries [2]. The most recent World Health Organization classification of Head and Neck Tumours distinguishes 22 histopathological subtypes of SGC, which makes each subtype even rarer [3]. Recognition of, and differentiation between these different subtypes is notoriously difficult and different subtypes exhibit different clinical features adding up to the complexity of the disease [4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research

Related Links:

CONCLUSION: This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone. PMID: 31796519 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract Although salivary gland cancers comprise only ∼3-6% of head and neck cancers, treatment options for patients with advanced-stage disease are limited. Because of their rarity, salivary gland malignancies are understudied compared to other exocrine tissue cancers. The comparative lack of progress in this cancer field is particularly evident when it comes to our incomplete understanding of the key molecular signals that are causal for the development and/or progression of salivary gland cancers. Using a novel conditional transgenic mouse (K5:RANKL), we demonstrate that Receptor Activator of NFkB Ligand (...
Source: Cytokine - Category: Molecular Biology Authors: Tags: Cytokine Source Type: research
Conclusions: TLG on restaging FDG-PET predicted PFS and OS in patients with RSGC; patients with predicted poor outcome may benefit from alternate, escalated treatment strategies. Multivariate analysis of clinicopathological and imaging parametersParameterPFS HR (95.0% CI)PFS p-valueOS HR (95.0% CI)OS p-valueHistologic subtype, Adenocarcinoma vs. Non-adenocarcinoma2.27 (1.33- 3.89)0.0031.60 (0.91-2.80)0.09TMTV1.01 (0.99-1.012)0.081.00 (1.00-1.011)0.14TLG1.00 (1.00-1.001)
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Head and Neck Posters Source Type: research
Conclusion Most head and neck pathologies show a broad cellular heterogeneity making it difficult to achieve an accurate diagnosis and efficient treatment (Graf and Zavodszky, 2017; Lo Nigro et al., 2017). Single cell analysis of circadian omics (Lande-Diner et al., 2015; Abraham et al., 2018), may be a crucial tool needed in the future to fully understand the circadian control of head and neck diseases. It becomes more obvious that there is only a small genetic component but a largely unknown epigenetics and/or environmental component for most of the head and neck pathologies (Moosavi and Motevalizadeh Ardekani, 2016; He...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Publication date: July–August 2018Source: Reports of Practical Oncology &Radiotherapy, Volume 23, Issue 4Author(s): Mateusz Szewczyk, Paweł Golusiński, Jakub Pazdrowski, Piotr Pieńkowski, Sławomir Marszałek, Jacek Sygut, Wojciech GolusińskiAbstractAimThe purpose of the study was to publish our experience of salivary gland cancer treatment with large number of patients treated at a single institution.BackgroundSalivary gland cancers are rare tumors of the head and neck representing about 5% of cancers in that region and about 0.5% of all malignancies. Due to the rarity of the disease, most of the studies reg...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
The androgen receptor (AR) is a nuclear steroid receptor that binds to testosterone and dihydrotestosterone and regulates the transcription of genes leading to cell growth, differentiation and survival. AR serves as an important oncogenic signal in prostate cancers and apocrine breast cancers. Salivary duct carcinoma (SDC) is a rare subtype of head and neck cancer that is defined by an apocrine phenotype, with AR positivity by immunohistochemistry (IHC) in up to 98% of cases [1]. A recent clinical trial with leuprorelin acetate and bicalutamide has shown promising activity with an overall response rate of 42% in AR-positiv...
Source: Oral Oncology - Category: Cancer & Oncology Authors: Tags: Letter to the editor Source Type: research
Conclusions This report shows a single institution results of oncological treatment in patients with malignant salivary gland tumors, where positive surgical margins strongly correlate with patients’ worse outcome. Whether to extend the procedure, which very often requires sacrificing the nerve is still a question of debate.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Head&Neck, EarlyView.
Source: Head and Neck - Category: ENT & OMF Authors: Source Type: research
The major salivary glands occur in three pairs (the parotid, submandibular, and the sublingual glands), while the minor salivary glands occur as several hundred structures scattered within the mucous membranes of the mouth, oropharynx, larynx, nose, and the paranasal sinuses. In France, the cancers of the major salivary glands are rare, with an estimated incidence of 0.7/100,000 person-years in men and 0.5/100,000 person-years in women [1], and account for 1.9% and 8.6% of head and neck cancers (HNC) in men and in women, respectively [2].
Source: Oral Oncology - Category: Cancer & Oncology Authors: Source Type: research
ConclusionAlthough the objective responses to eribulin were uncommon, disease control was observed in the majority of patients.
Source: Head and Neck - Category: ENT & OMF Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Head and Neck Cancer | International Medicine & Public Health | Salivary Gland Cancer | WHO